联合检测血清肿瘤标志物对肺癌的诊断价值

目的评价5项血清肿瘤标志物癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原19-9(CA19-9)、神经元特异性烯醇化酶(NSE)和铁蛋白(SF)联合检测对提高肺癌临床诊断的价值。方法采用多肿瘤标志物蛋白芯片检测系统分别测定73例肺癌患者、21例良性肺病患者以及16例健康人血清中CEA、CA125、CA19-9、NSE和SF的水平,比较3组间的差异。结果肺癌组患者血清中CEA、CA125、CA19-9、NSE和SF的水平均显著高于良性肺病组及健康组(P<0.01)。其中CEA、CA125、CA19-9、NSE和SF诊断肺癌的灵敏度分别为79.5%、56.2%、56.2%、52.1%和57.5%;而诊断特异性分别达到81.0%、100%、85.7%、90.5%和80.9%。5项标志物联合检测的灵敏度和特异性则更高。结论CEA、CA125、CA19-9、NSE和SF对非小细胞肺癌(NSCLC)具有较高的辅助诊断价值,5项标志物联合检测可显著提高肺癌诊断的灵敏度和特异性。

Clinical Significance of Serum Levels of Combined Tumor Markers(TM) in Diagnosis of Lung Cancer

Objective To evaluate the application of combined five tumor markers, CEO, CA125, CA199, NSE and SF in diagnosing lung cancer in terms of enhancement in the early detection rate. Methods Using tumor markers protein chip, the serum CEA, CA125, CA19-9, NSE and SF levels in 73 cases of non-small cell lung cancer (NSCLC), 21 cases of benign pulmonary disease and 16 cases of normal controls were measured and compared. Results The levels of CEA, CA125, CA19-9, NSE and SF in patients with NSCLC were significantly higher than those in the group with benign lung diseases and in the control group( P <0.01). The sensitivity of CEA, CA125, CA19-9, NSE and SF were 79.5%, 56.2%, 56.2%, 52.1%, 57.5%, respectively, and the corresponding specificity 81.0%, 100%, 85.7%, 90.5%, 80.9%, respectively. Moreover, the sensitivity and specificity of the combined determinations including the five tumor markers were higher than those of the respective determination. Conclusion The serum CEA, CA125, CA19-9, NSE and SF levels are very valuable in diagnosis of lung cancer. The combined detection five tumor markers is recommended in clinical work.